Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.

Area of Science:

• Reproductive Endocrinology
• Pharmacology
• Women's Health

Background:

• Tissue selective estrogen complexes (TSEC) combine selective estrogen receptor modulators (SERMs) with estrogens, exhibiting varied tissue-specific effects.
• Preclinical studies indicated bazedoxifene (BZA) has a neutral effect on mammary and endometrial tissues, and an antagonist effect when combined with conjugated estrogens (CE).

Purpose of the Study:

• To evaluate the efficacy and safety of the BZA/CE TSEC in postmenopausal women.
• To compare BZA/CE with traditional hormone therapy regarding menopausal symptom relief, bone loss prevention, and safety endpoints.

Main Methods:

• Large, randomized clinical trials were conducted using two doses of BZA/CE (20 mg/0.45 mg and 20 mg/0.625 mg).
• Outcomes assessed included menopausal symptom reduction, bone mineral density, safety on breast, endometrium, and ovary, and incidence of cardiovascular and venous thrombosis events.

Main Results:

• BZA/CE significantly reduced menopausal symptoms and prevented bone loss.
• The TSEC showed a favorable safety profile, with cardiovascular and venous thrombosis event rates similar to placebo.
• Improvements in sleep, quality of life, and treatment satisfaction were observed.
• Compared to progestogen-containing hormone therapy, BZA/CE resulted in higher amenorrhea rates and reduced breast pain.

Conclusions:

• The BZA/CE TSEC is an effective and safe option for managing menopausal symptoms and preventing bone loss in postmenopausal women.
• This TSEC offers benefits over traditional hormone therapy, including improved tolerability on breast tissue.
• Further rigorous clinical trials are needed for other emerging TSECs identified in preclinical research.